1
|
Lázaro CM, de Oliveira CC, Gambero A, Rocha T, Cereda CMS, de Araújo DR, Tofoli GR. Evaluation of Budesonide-Hydroxypropyl-β-Cyclodextrin Inclusion Complex in Thermoreversible Gels for Ulcerative Colitis. Dig Dis Sci 2020; 65:3297-3304. [PMID: 31974913 DOI: 10.1007/s10620-020-06075-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Accepted: 01/12/2020] [Indexed: 12/18/2022]
Abstract
BACKGROUND New formulations for topical treatment of ulcerative colitis with budesonide inclusion complex (BUDHP-β-CD) and poloxamers (PL) were developed for future clinical use. AIMS This study evaluated the efficacy of such novel formulations in a rat model of colitis. METHODS The PL-BUDHP-β-CD systems were prepared by direct dispersion of the complex (BUD concentration 0.5 mg mL-1) in solutions with PL407 or PL403. Male Wistar rats underwent TNBS-induced colitis and were treated for 5 days by a rectal route, as follows: BUD 1: BUDHP-β-CD + PL407 (18%); BUD 2: BUDHP-β-CD + PL407 (20%); BUD 3: BUDHP-β-CD + PL407 (18%) + PL403 (2%); BUD 4: plain BUD; BUD 5: BUDHP-β-CD; C1: HP-β-CD + PL407 (18%); C2: HP-β-CD + PL407 (20%); C3: HP-β-CD + PL407 (18%) + PL403 (2%); C4: saline. A negative control group without colitis was also used. Colitis was assessed via myeloperoxidase (MPO) activity, and macroscopic and microscopic damage score in colon tissues. Protein levels of TNF-α, IL-1β, IL-10 and endogenous glucocorticoids were obtained using ELISA. RESULTS BUDHP-β-CD poloxamer formulations had similar MPO activity when compared with the negative control group. All formulations presented lower MPO activity than BUDHP-β-CD and plain BUD (p < 0.001). BUD 2 produced lower microscopic score values than plain BUD and BUDHP-β-CD (p < 0.01). All formulations with BUDHP-β-CD poloxamers reduced TNF-α levels (p < 0.05). CONCLUSION Novel budesonide inclusion complex formulations improved microscopic damage and reduced colonic MPO activity and TNF-α levels.
Collapse
Affiliation(s)
- Carolina Martins Lázaro
- Universidade São Francisco, Av. São Francisco de Assis 218, Bragança Paulista, São Paulo, 12916-900, Brazil
| | - Carolina C de Oliveira
- Universidade São Francisco, Av. São Francisco de Assis 218, Bragança Paulista, São Paulo, 12916-900, Brazil
| | - Alessandra Gambero
- Universidade Estadual de Campinas, Av. Alexandre Cazelatto 999, Paulínia, 13140-000, São Paulo, Brazil
| | - Thalita Rocha
- Universidade São Francisco, Av. São Francisco de Assis 218, Bragança Paulista, São Paulo, 12916-900, Brazil
| | - Cintia Maria Saia Cereda
- Faculdade São Leopoldo Mandic, Instituto de Pesquisa São Leopoldo Mandic, Rua José Rocha Junqueira 13, Campinas, São Paulo, 13045-75, Brazil
| | - Daniele Ribeiro de Araújo
- Universidade Federal do ABC, Av. dos Estados 5001, Bl A, Torre 3, Lab 503-3, Santo André, São Paulo, 09210-170, Brazil
| | - Giovana Radomille Tofoli
- Faculdade São Leopoldo Mandic, Instituto de Pesquisa São Leopoldo Mandic, Rua José Rocha Junqueira 13, Campinas, São Paulo, 13045-75, Brazil.
| |
Collapse
|
3
|
Cereda CMS, Mecatti DS, Papini JZB, Bueno DV, Franz-Montan M, Rocha T, Pedrazzoli Júnior J, de Paula E, de Araújo DR, Grillo R, Fraceto LF, Calafatti SA, Tofoli GR. Bupivacaine in alginate and chitosan nanoparticles: an in vivo evaluation of efficacy, pharmacokinetics, and local toxicity. J Pain Res 2018; 11:683-691. [PMID: 29670395 PMCID: PMC5896646 DOI: 10.2147/jpr.s158695] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Objective This study reports a preclinical evaluation of an alginate/chitosan nanoparticle formulation containing NovaBupi®, a racemic bupivacaine (BVC) containing 25% dextrobupivacaine and 75% levobupivacaine. Methods New Zealand White rabbits (n=6) received intraoral or intrathecal injections of BVC 0.5% or BVC 0.5%-loaded alginate–chitosan nanoparticles (BVCALG). BVC plasma levels and pharmacokinetic parameters were determined in blood samples of these rabbits. An infraorbital nerve blockade was performed in male Wistar rats (n=7) with the same formulations and the vehicle (NPALG). Histological evaluation of local toxicity after 6 hours and 24 hours of the treatments was performed in rats’ (n=6) oral tissues. Results No statistically significant difference was observed between plasma concentrations and pharmacokinetic parameters (p>0.05) after intraoral injections. However, after intrathecal injection BVCALG changed approximately three times the values of volume of distribution and area under the curve (AUC0–t; p<0.05). The total analgesic effect of BVC after infraorbital nerve blockade was improved by 1.4-fold (p<0.001) with BVCALG. BVC and BVCALG did not induce significant local inflammatory reaction. Conclusion The encapsulation of BVC prolongs the local anesthetic effect after infraorbital nerve blockade and altered the pharmacokinetics after intrathecal injection.
Collapse
Affiliation(s)
| | | | | | | | - Michelle Franz-Montan
- Department of Physiological Sciences, University of Campinas, Piracicaba, São Paulo, Brazil
| | - Thalita Rocha
- UNIFAG, São Francisco University, Bragança Paulista, São Paulo, Brazil
| | | | - Eneida de Paula
- Department of Biochemistry and Tissue Biology, University of Campinas, Campinas, São Paulo, Brazil
| | | | - Renato Grillo
- Department of Physics and Chemistry, School of Engineering, São Paulo State University (UNESP), Ilha Solteira, São Paulo, Brazil
| | - Leonardo Fernandes Fraceto
- Department of Environmental Engineering, São Paulo State University (UNESP), Sorocaba, São Paulo, Brazil
| | | | | |
Collapse
|